The Bull Case For Eli Lilly (LLY) Could Change Following New Multi‑Target R&D Alliances With Biotechs

• In recent days, Abbisko Therapeutics and BioArctic each announced new research and license agreements with Eli Lilly, adding multi-target discovery work worth up to about US$1.90 billion in milestones for Abbisko and up to US$770 million for BioArctic, alongside royalties on any future product sales.

• These alliances, paired with Lilly's ongoing advances in obesity, oncology, and neurodegeneration programs, underline how external partnerships are being used to broaden its pipeline beyond its flagship GLP‑1 franchise.

• We'll now examine how Lilly's expanded collaborations, particularly the multi-program Abbisko deal, may influence the existing investment narrative around growth, risk, and concentration.

We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Eli Lilly Investment Narrative Recap

To own Eli Lilly, you need to believe its GLP‑1 obesity and diabetes franchise can keep driving growth while a broader pipeline slowly reduces product concentration risk. The Abbisko and BioArctic partnerships incrementally support that diversification, but they do not materially change the key short term catalyst, which remains execution and access on GLP‑1s, or the biggest risk around pricing pressure and reimbursement pushback on obesity drugs.

Among recent announcements, the Q1 2026 results and lifted full year revenue guidance to US$82 billion to US$85 billion are most relevant. They anchor today's GLP‑1 driven narrative that these new Abbisko and BioArctic deals are being layered on top of a franchise that is already carrying the financial story, rather than replacing it, which matters when thinking about how much concentration risk you are willing to accept.

Yet while Lilly's partnerships hint at a wider future beyond GLP‑1s, investors should be aware that concentrated dependence on a few obesity drugs still leaves the story vulnerable to...

Read the full narrative on Eli Lilly (it's free!)

Eli Lilly's narrative projects $113.8 billion revenue and $46.8 billion earnings by 2029. This requires 16.4% yearly revenue growth and about a $21.5 billion earnings increase from $25.3 billion today.

Uncover how Eli Lilly's forecasts yield a $1219 fair value , a 9% upside to its current price.

Exploring Other Perspectives

Some of the lowest priced analysts were already assuming around US$102 billion of revenue and US$40 billion of earnings by 2029, yet they still see obesity pricing reforms and tighter safety scrutiny as reasons to be more cautious than consensus, so if you are weighing the new Abbisko and BioArctic deals, it is worth comparing how your own expectations stack up against those more conservative views.